New piperidine derivative

Abstract

The present invention provides a novel piperidine compound of the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R>1< represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, etc., or a group of the formula: (a) wherein R>11< AND R>12< are the same or different, and each represents hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, etc., R>2< represents hydrogen atom, etc., Z represents oxygen atom or a group represented by -N(R>3<)-, R>3< represents hydrogen atom or an alkyl group, etc., R>4< represents hydrogen atom or an alkyl group, etc.,or a pharmaceutically acceptable salt thereof.

Description

technical field

[0001] The present invention relates to novel piperidine compounds having excellent tachykinin receptor antagonism. Background technique

[0002] Tachykinin is a general name for a group of neuropeptides, and substance P (hereinafter referred to as SP), neurokinin-A, and neurokinin-B have been known in mammals. These peptides are known to exhibit various types of biological activities by binding to their corresponding receptors (neurokinin-1, neurokinin-2, neurokinin-3) present in vivo. Among them, SP is one of those with the longest history among neuropeptides and has been studied in detail. Its existence was confirmed in 1931 in extracts of horse intestinal tubes, and it is a peptide containing 11 amino acids, the structure of which was determined in 1971.

[0003] SP widely exists in the peripheral nervous system, and it has physiological activities such as vasodilation, vascular permeability promotion, smooth muscle contraction, excessive nerve excitabi...

Images